<DOC>
	<DOC>NCT00049946</DOC>
	<brief_summary>A Placebo Controlled Study For Patients With Schizophrenia</brief_summary>
	<brief_title>Schizophrenia Study In Adults</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<criteria>Patient must meet diagnostic criteria for schizophrenia. Patients with other psychotic disorders. Patients whose condition is due to the direct physiological effects of a substances (e.g., drug abuse) or a general medical condition. Patients with a history of autistic disorder or another pervasive developmental disorder. Patients with epilepsy or a history of seizures requiring treatment. Patients who are excluded from taking the drug risperidone. Patients who pose a current serious suicidal or homicidal risk. Patients who are adequately stabilized on their treatment.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Talnetant</keyword>
	<keyword>schizophrenia</keyword>
	<keyword>NK3 receptor antagonist</keyword>
	<keyword>psychosis</keyword>
</DOC>